Transforming Cancer Therapeutics & Precision Medicine
Through
NOVEL BIOMARKER DISCOVERY
We Are a Group of Researchers Driving Innovation in Biomarker Discovery
Breakthrough in Finding Cancer Specific Targets
Targeted immunotherapy is the leading approach for combating cancer. A key challenge has been to identify cancer-specific antigens that are suitable for antibody-based therapeutics.
Finding new targets that are only on the surface of cancer cells and not on normal cells is the single most important step to creating new effective therapies and minimize or eliminate treatment side effects.
Our cutting-edge Oncotope Platform has revolutionized the discovery of cancer-specific antigens. Remarkably, it can identify multiple new antigens on any cancer type in a matter of months.
Using this groundbreaking platform, we identified 8 new antigen targets, that are present on the surface of Prostate Cancer and Breast Cancer, including Triple Negative Breast Cancer cells and generated matching therapeutic antibodies.
In addition to Breast Cancer, the Oncotope Platform has successfully generated antibodies targeting Melanoma and Prostate Cancer.
Key Points
1
Oncotope Platform
Our Oncotope Platform rapidly identifies multiple cancer specific targets and simultaneously generates therapeutic antibodies against these targets.
2
New Surface Antigens
We identified and therapeutically validated new targets on the surface of Prostate Cancer and Breast Cancer cells, including Triple Negative, that are not on normal cells.
3
Therapeutic Antibodies
Antibody-drug conjugates (ADCs) directed against these targets kill cancer cells without harming normal cells.
4
Multiple Cancers
Our Platform has been successfully tested with Breast Cancer, Prostate Cancer and Melanoma. The platform can be applied to all types of cancer.
Publication & Presentation
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2022
The American Society of Clinical Oncology (ASCO) is the world’s premier cancer research organization.
Our study establishing the Oncotope Platform as a new method for the discovery of unique cancer specific targets was presented at the 2022 ASCO Annual Meeting.
AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2024
The American Association for Cancer Research (AACR) is the world’s oldest and largest professional association related to cancer research.
Our study identifying a novel Breast Cancer target was presented at the 2024 AACR Annual Meeting.
SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) 2025
The San Antonio Breast Cancer Symposium is the largest breast cancer research meeting in the world.
Our study showing our new target as a tumor-specific antigen enabling precision immunotherapy in Breast cancer.
About Us
Cancer Antibodies Inc. (CAI), is a 501(c)(3) non-profit cancer research organization dedicated to using novel methods to identify unique antigenic sites on cancer cells for diagnostics and therapeutics. Our organization is a team of scientific researchers in cancer, biophysics, neuroscience, artificial intelligence and passionate advocates for advancements in cancer therapy.
Collaborations
Collaboration is at the heart of our mission to advance breakthrough cancer research. We recognize that meaningful progress in cancer treatment and diagnostics requires the collective expertise of scientists, clinicians, and research institutions worldwide.
Some our current collaborations include University of Miami Sylvester Comprehensive Cancer Center, UVA Comprehensive Cancer Center, Moffitt, MD Anderson, AdventHealth and The Medical College of Georgia.
We actively seek partnerships with researchers and institutions who share our commitment to identifying novel cancer-specific targets and developing innovative immunotherapies.